应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
JBIO Jade Biosciences
休市中 04-02 16:00:00 EDT
15.49
-0.53
-3.31%
盘后
15.49
+0.00
0.00%
18:43 EDT
最高
16.19
最低
15.22
成交量
40.33万
今开
15.52
昨收
16.02
日振幅
6.02%
总市值
7.62亿
流通市值
5.11亿
总股本
4,922万
成交额
631.31万
换手率
1.22%
流通股本
3,300万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Jade Biosciences, Inc.盘中异动 早盘快速上涨5.68%报15.25美元
市场透视 · 03-10
Jade Biosciences, Inc.盘中异动 早盘快速上涨5.68%报15.25美元
Jade Biosciences预计2026年中启动IgAN患者二期临床试验 初步数据有望2027年公布
美股速递 · 03-06
Jade Biosciences预计2026年中启动IgAN患者二期临床试验 初步数据有望2027年公布
Jade Biosciences公司:截至2025年12月31日持有3.36亿美元现金及投资,预计资金可支撑运营至2028年上半年
美股速递 · 03-06
Jade Biosciences公司:截至2025年12月31日持有3.36亿美元现金及投资,预计资金可支撑运营至2028年上半年
Jade Biosciences, Inc.盘中异动 早盘急速下跌5.64%报16.06美元
市场透视 · 01-23
Jade Biosciences, Inc.盘中异动 早盘急速下跌5.64%报16.06美元
Jade Biosciences申请出售320万股普通股- SEC备案
美股速递 · 2025-12-23
Jade Biosciences申请出售320万股普通股- SEC备案
Jade Biosciences提交最多1610万股普通股的出售申请 - SEC备案
投资观察 · 2025-11-20
Jade Biosciences提交最多1610万股普通股的出售申请 - SEC备案
Jade Biosciences Inc 提交出售股东最多 1610 万股普通股的注册申请 - SEC备案
美股速递 · 2025-11-15
Jade Biosciences Inc 提交出售股东最多 1610 万股普通股的注册申请 - SEC备案
Jade Biosciences宣布推出Jade201——一款在研的潜在同类最佳半衰期延长去岩藻糖化抗BAFF受体单克隆抗体,用于治疗自身免疫性疾病
美股速递 · 2025-10-07
Jade Biosciences宣布推出Jade201——一款在研的潜在同类最佳半衰期延长去岩藻糖化抗BAFF受体单克隆抗体,用于治疗自身免疫性疾病
加载更多
公司概况
公司名称:
Jade Biosciences
所属市场:
NASDAQ
上市日期:
--
主营业务:
Jade Biosciences, Inc.最初于2018年7月27日作为特拉华州的Aerovate Therapeutics, Inc.注册成立。在2025年4月完成合并和注册地变更后,该公司现为内华达州公司,专注于为自身免疫性疾病患者开发新型生物疗法。其主要候选药物JADE101靶向APRIL用于治疗IgA肾病,另有针对BAFF-R及其他未披露通路的项目。
发行价格:
--
{"stockData":{"symbol":"JBIO","market":"US","secType":"STK","nameCN":"Jade Biosciences","latestPrice":15.49,"timestamp":1775160000000,"preClose":16.02,"halted":0,"volume":403279,"hourTrading":{"tag":"盘后","latestPrice":15.49,"preClose":15.49,"latestTime":"18:43 EDT","volume":3911,"amount":60580.55,"timestamp":1775169821710,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.03308364544319597,"floatShares":33002000,"shares":49218491,"eps":-3.193116,"marketStatus":"休市中","change":-0.53,"latestTime":"04-02 16:00:00 EDT","open":15.52,"high":16.185,"low":15.22,"amount":6313100.859575,"amplitude":0.060237,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.193116,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":7,"adr":0,"listingDate":1625025600000,"exchange":"NASDAQ","adjPreClose":16.02,"preHourTrading":{"tag":"盘前","latestPrice":15.27,"preClose":16.02,"latestTime":"08:11 EDT","volume":1143,"amount":14224.630428,"timestamp":1775131909321,"change":-0.75,"changeRate":-0.046816,"amplitude":0.277154},"postHourTrading":{"tag":"盘后","latestPrice":15.49,"preClose":15.49,"latestTime":"18:43 EDT","volume":3911,"amount":60580.55,"timestamp":1775169821710,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5599182751398125,"impliedVol":0.6968,"impliedVolPercentile":0.516},"requestUrl":"/m/hq/s/JBIO","defaultTab":"news","newsList":[{"id":"2618946801","title":"Jade Biosciences, Inc.盘中异动 早盘快速上涨5.68%报15.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618946801","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618946801?lang=zh_cn&edition=full","pubTime":"2026-03-10 22:22","pubTimestamp":1773152551,"startTime":"0","endTime":"0","summary":"北京时间2026年03月10日22时22分,Jade Biosciences, Inc.股票出现波动,股价大幅拉升5.68%。Jade Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为1.37%。Jade Biosciences, Inc.公司简介:Jade Biosciences Inc专注于开发疗法,以解决自身免疫性疾病中尚未满足的关键需求。Jade是基于 Fairmount创立的抗体发现引擎Paragon Therapeutics许可的资产推出的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310222232a6b5b7e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310222232a6b5b7e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","JBIO","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135114107","title":"Jade Biosciences预计2026年中启动IgAN患者二期临床试验 初步数据有望2027年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1135114107","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135114107?lang=zh_cn&edition=full","pubTime":"2026-03-06 20:05","pubTimestamp":1772798719,"startTime":"0","endTime":"0","summary":"Jade Biosciences宣布,公司计划于2026年中期启动针对IgA肾病(IgAN)患者的二期临床试验。根据最新规划,该项研究的初步数据预计将在2027年正式披露。\n此次临床试验的推进标志着公司在肾脏疾病治疗领域取得重要进展。通过二期试验,研究人员将深入评估候选药物的安全性与有效性,为后续临床开发提供关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","JBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106105650","title":"Jade Biosciences公司:截至2025年12月31日持有3.36亿美元现金及投资,预计资金可支撑运营至2028年上半年","url":"https://stock-news.laohu8.com/highlight/detail?id=1106105650","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106105650?lang=zh_cn&edition=full","pubTime":"2026-03-06 20:03","pubTimestamp":1772798594,"startTime":"0","endTime":"0","summary":"截至2025年12月31日,Jade Biosciences公司持有的现金、现金等价物及投资总额达到3.36亿美元。这一资金规模预计将为公司提供充足的运营支持,使其能够持续开展研发与商业活动直至2028年上半年。\n充足的流动性为Jade Biosciences推进其生物科技管线提供了战略灵活性。公司管理层表示,现有资金将重点用于核心项目的临床研究和技术平台优化。财务储备的稳定性有助于降低短期融资需求带来的不确定性,为长期价值创造奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605960287","title":"Jade Biosciences, Inc.盘中异动 早盘急速下跌5.64%报16.06美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605960287","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605960287?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:34","pubTimestamp":1769178875,"startTime":"0","endTime":"0","summary":"北京时间2026年01月23日22时34分,Jade Biosciences, Inc.股票出现异动,股价急速跳水5.64%。Jade Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.17%。Jade Biosciences, Inc.公司简介:Jade Biosciences Inc专注于开发疗法,以解决自身免疫性疾病中尚未满足的关键需求。Jade是基于 Fairmount创立的抗体发现引擎Paragon Therapeutics许可的资产推出的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012322343697a32868&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012322343697a32868&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["JBIO","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166711556","title":"Jade Biosciences申请出售320万股普通股- SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1166711556","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166711556?lang=zh_cn&edition=full","pubTime":"2025-12-23 05:41","pubTimestamp":1766439668,"startTime":"0","endTime":"0","summary":"Jade Biosciences申请出售320万股普通股- SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168065668","title":"Jade Biosciences提交最多1610万股普通股的出售申请 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1168065668","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168065668?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:50","pubTimestamp":1763574644,"startTime":"0","endTime":"0","summary":"11月14日 - Jade Biosciences Inc: *Jade Biosciences Inc提交最多1610万股普通股的出售申请 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138728748","title":"Jade Biosciences Inc 提交出售股东最多 1610 万股普通股的注册申请 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1138728748","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138728748?lang=zh_cn&edition=full","pubTime":"2025-11-15 05:16","pubTimestamp":1763154970,"startTime":"0","endTime":"0","summary":"Jade Biosciences Inc 提交出售股东最多 1610 万股普通股的注册申请 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","JBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176630375","title":"Jade Biosciences宣布推出Jade201——一款在研的潜在同类最佳半衰期延长去岩藻糖化抗BAFF受体单克隆抗体,用于治疗自身免疫性疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=1176630375","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176630375?lang=zh_cn&edition=full","pubTime":"2025-10-07 19:05","pubTimestamp":1759835128,"startTime":"0","endTime":"0","summary":"Jade Biosciences宣布推出Jade201——一款在研的潜在同类最佳半衰期延长去岩藻糖化抗BAFF受体单克隆抗体,用于治疗自身免疫性疾病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","JBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.jadebiosciences.com","stockEarnings":[{"period":"1week","weight":0.1104},{"period":"1month","weight":0.1136},{"period":"3month","weight":0.0939},{"period":"6month","weight":0.7483},{"period":"1year","weight":-0.8244},{"period":"ytd","weight":0.0039}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Jade Biosciences, Inc.最初于2018年7月27日作为特拉华州的Aerovate Therapeutics, Inc.注册成立。在2025年4月完成合并和注册地变更后,该公司现为内华达州公司,专注于为自身免疫性疾病患者开发新型生物疗法。其主要候选药物JADE101靶向APRIL用于治疗IgA肾病,另有针对BAFF-R及其他未披露通路的项目。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.072791},{"month":2,"riseRate":0.4,"avgChangeRate":-0.004913},{"month":3,"riseRate":0.6,"avgChangeRate":0.191335},{"month":4,"riseRate":0.4,"avgChangeRate":-0.275485},{"month":5,"riseRate":0,"avgChangeRate":-0.15923},{"month":6,"riseRate":0.75,"avgChangeRate":-0.046284},{"month":7,"riseRate":0.6,"avgChangeRate":-0.036},{"month":8,"riseRate":0.6,"avgChangeRate":0.058197},{"month":9,"riseRate":0.6,"avgChangeRate":0.018606},{"month":10,"riseRate":0.6,"avgChangeRate":0.005142},{"month":11,"riseRate":0.6,"avgChangeRate":0.137722},{"month":12,"riseRate":0.8,"avgChangeRate":0.213367}],"exchange":"NASDAQ","name":"Jade Biosciences","nameEN":"Jade Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jade Biosciences(JBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Jade Biosciences(JBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Jade Biosciences,JBIO,Jade Biosciences股票,Jade Biosciences股票老虎,Jade Biosciences股票老虎国际,Jade Biosciences行情,Jade Biosciences股票行情,Jade Biosciences股价,Jade Biosciences股市,Jade Biosciences股票价格,Jade Biosciences股票交易,Jade Biosciences股票购买,Jade Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jade Biosciences(JBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Jade Biosciences(JBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}